Research

Teleflex to Showcase Barrigel Rectal Spacer Studies at ASTRO 2024

- by Timothy Alexander
Teleflex Incorporated

WAYNE, PA — Teleflex Incorporated (NYSE: TFX) is set to present three pivotal clinical studies on its Barrigel™ rectal spacer at the American Society for Radiation Oncology (ASTRO) Annual Meeting, taking place in Washington, DC, from September 29 to October 2, 2024. These presentations aim to expand the clinical understanding of Barrigel™, the sole commercial hyaluronic acid rectal spacer designed to shield the rectum during prostate cancer radiation therapy.

Barrigel™ is a Non-Animal Stabilized Hyaluronic Acid (NASHA) spacer that significantly mitigates radiation to the rectum, aiming to enhance patient quality of life. It has been shown to reduce radiation exposure effectively in 98.5% of prostate cancer patients with T1-T3b disease.

The presentations include:

  1. Impact of Hyaluronic Acid (HA) Rectal Spacer Quality Score on Rectal Dosimetry and Gastrointestinal Toxicity Outcomes
    • Date: October 1, 2:30-3:45 p.m. ET, Hall C
    • Focus: Retrospective review on the implant quality and GI toxicity in prostate cancer patients treated with hypofractionated EBRT.
  2. Rectal Wall Infiltration with Hyaluronic Acid Based Rectal Spacer Reversal Protocol
    • Date: October 1, 2:30-3:45 p.m. ET, Hall C
    • Focus: Outcomes following rectal wall infiltration during Barrigel™ use.
  3. Hyaluronic Acid Rectal Spacer in Locally Recurrent Prostate Cancer Post-Radiation
    • Date: October 1, 2:30-3:45 p.m. ET, Hall C
    • Focus: Evaluation of Barrigel™ in recurrent prostate cancer patients receiving SBRT.

Teleflex will also host a Barrigel™ Educational Symposium on September 30 at the REACH at the John F. Kennedy Center for Performing Arts. The symposium, titled “The Science of Personalized Spacing,” will feature expert discussions on best practices in challenging cases.

Additionally, the Teleflex booth (1223) at the ASTRO Exhibit Hall will offer interactive demonstrations of the Barrigel™ procedure and clinical discussions led by Dr. Michael Greenberg and Dr. John Han-Chih Chang on September 29 and 30. This event highlights Teleflex’s efforts to advance cancer care and improve patient outcomes with innovative solutions.

READ:  Ocugen to Present at Oppenheimer Movers in Rare Disease Summit

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.